The rise and rise of stealth nanocarriers for cancer therapy: Passive versus active targeting

Nanomedicine

Volumn 5, Issue 9, 2010, Pages 1415-1433

  Huynh, Ngoc Trinh ^a   Roger, Emilie ^a   Lautram, Nolwenn ^a   Benoît, Jean Pierre ^a   Passirani, Catherine ^a  

^a UNIVERSITÉ D'ANGERS   (France)

Author keywords

anticancer drug; enhanced permeability and retention effect; EPR effect; ligand; long circulating nanocarriers; PEGylation; targeted nanoparticles

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; BELOTECAN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LIPOPLATIN; MACROGOL; MBP 426; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; NANOCARRIER; NANOPARTICLE; NANOPLATIN; NANOXEL; OXALIPLATIN; PACLITAXEL; PAXEN; PEPTIDE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLON CANCER; COLON CARCINOMA; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GASTROINTESTINAL CARCINOMA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; KAPOSI SARCOMA; LEWIS CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MYALGIA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMACH CANCER; STOMATITIS; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 78650053505     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.113     Document Type: Review

References (208)

1. Singh R, Lillard JW Jr: Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86(3), 215-223 (2009).
2. Moghimi SM, Hunter AC, Murray JC: Long-circulating and target-specifc nanoparticles: theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001).
3. Passirani C, Benoit JP: Complement activation by injectable colloidal drug carriers. In: Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids. CRC Press, Inc., FL, USA 187-230 (2005).
4. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (1-2), 271-284 (2000).
5. van Vlerken LE, Vyas TK, Amiji MM: Poly(ethylene glycol)-modifed nanocarriers for tumor-targeted and intracellular delivery Pharm. Res. 24(8), 1405-1414 (2007).
6. Morille M, Montier T, Legras P et al.: Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials 31(2), 321-329 (2010).
7. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP: Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29(24-25), 3477-3496 (2008).
8. David S, Pitard B, Benoit JP, Passirani C: Non-viral nanosystems for systemic siRNA delivery. Pharmacol. Res. 62(2), 100-114 (2009).
9. Jones A, Harris AL: New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. Cancer J. Sci. Am. 4(4), 209-217 (1998).
10. Konerding MA, Fait E, Gaumann A: 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br. J. Cancer 84(10), 1354-1362 (2001).
11. Baban DF, Seymour LW: Control of tumor vascular permeability. Adv. Drug Deliv. Rev. 34(1), 109-119 (1998).
12. Jang SH, Wientjes MG, Lu D, Au JL: Drug delivery and transport to solid tumors. Pharm. Res. 20(9), 1337-1350 (2003).
13. Hobbs SK, Monsky WL, Yuan F et al.: Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95(8), 4607-4612 (1998).
14. Maeda H, Matsumura Y: Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6(3), 193-210 (1989).
15. Koo OM, Rubinstein I, Onyuksel H: Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 1(3), 193-212 (2005).
16. Vonarbourg A, Passirani C, Saulnier P, Benoit JP: Parameters infuencing the stealthiness of colloidal drug delivery systems. Biomaterials 27(24), 4356-4373 (2006).
17. Lemarchand C, Gref R, Couvreur P: Polysaccharide-decorated nanoparticles. Eur. J. Pharm. Biopharm. 58(2), 327-341 (2004).
18. Lemarchand C, Gref R, Passirani C et al.: Infuence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials 27(1), 108-118 (2006).
19. Kommareddy S, Tiwari SB, Amiji MM: Long-circulating polymeric nanovectors for tumor-selective gene delivery Technol. Cancer Res. Treat. 4(6), 615-625 (2005).
20. Wang M, Thanou M: Targeting nanoparticles to cancer. Pharmacol. Res. 62(2), 90-99 (2010).
21. Allen TM, Chonn A: Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 223(1), 42-46 (1987).
22. Leserman LD, Barbet J, Kourilsky F, Weinstein JN: Targeting to cells of fuorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 288(5791), 602-604 (1980).
23. Leserman LD, Weinstein JN, Blumenthal R, Terry WD: Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc. Natl Acad. Sci. USA 77(7), 4089-4093 (1980).
24. Crown J, O'Leary M: The taxanes: an update. Lancet 355(9210), 1176-1178 (2000).
25. Gelderblom H, Verweij J, Nooter K, Sparreboom A: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37(13), 1590-1598 (2001).
26. van Zuylen L, Verweij J, Sparreboom A: Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 19(2), 125-141 (2001).
27. Singla AK, Garg A, Aggarwal D: Paclitaxel and its formulations. Int. J. Pharm. 235(1-2), 179-192 (2002).
28. Cortes J, Saura C: Nanoparticle albumin-bound (nab™)-paclitaxel: improving effcacy and tolerability by targeted drug delivery in metastatic breast cancer. Eur. J. Cancer Suppl. 8(1), 1-10 (2010).
29. Hawkins MJ, Soon-Shiong P, Desai N: Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 60(8), 876-885 (2008)
30. Kim SC, Kim DW, Shim YH et al.: In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and effcacy. J. Control. Release 72(1-3), 191-202 (2001).
31. Kim TY, Kim DW, Chung JY et al.: Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 10(11), 3708-3716 (2004).
32. Saif MW, Podoltsev NA, Rubin MS et al.: Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest. 28(2), 186-194 (2010).
33. Lee KS, Chung HC, Im SA et al.: Multicenter Phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 108(2), 241-250 (2008).
34. Park SR, Oh DY, Kim DW et al.: A multi-center, late Phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol. Rep. 12(5), 1059-1064 (2004).
35. Wang X, Wang Y, Chen ZG, Shin DM: Advances of cancer therapy by nanotechnology Cancer Res. Treat. 41(1), 1-11 (2009).
36. Yeh ET, Tong AT, Lenihan DJ et al.: Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109(25), 3122-3131 (2004).
37. Thigpen JT, Aghajanian CA, Alberts DS et al.: Role of PEGylated liposomal doxorubicin in ovarian cancer. Gynecol. Oncol. 96(1), 10-18 (2005).
38. Ranson MR, Cheeseman S, White S, Margison J: Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit. Rev. Oncol. Hematol 37(2), 115-120 (2001).
39. Gabizon A, Shmeeda H, Barenholz Y: Pharmacokinetics of PEGylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42(5), 419-436 (2003).
40. Solomon R, Gabizon AA: Clinical pharmacology of liposomal anthracyclines: focus on PEGylated liposomal doxorubicin. Clin. Lymphoma Myeloma 8(1), 21-32 (2008)
41. Gabizon AA: PEGylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19(4), 424-436 (2001).
42. Verma S, Dent S, Chow BJ, Rayson D, Safra T: Metastatic breast cancer: the role of PEGylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat. Rev. 34(5), 391-406 (2008).
43. Venne A, Li S, Mandeville R, Kabanov A, Alakhov V: Hypersensitizing effect of Pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 56(16), 3626-3629 (1996).
44. Alakhov V, Klinski E, Li S et al.: Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B. Biointerfaces 16(1-4), 113-134 (1999).
45. Danson S, Ferry D, Alakhov V et al.: Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 90(11), 2085-2091 (2004).
46. Duska LR, Penson R, Supko JG et al.: A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. Clin. Cancer Res. 5(6), 1299-1305 (1999).
47. Valle JW, Armstrong A, Newman C et al.: A Phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs 1-9 (2010).
48. Geh JI, Glynne-Jones R, Kwok QS et al.: Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. Clin. Oncol. (R. Coll. Radiol.) 12(3), 182-187 (2000).
49. Ilson DH: Cancer of the gastroesophageal junction: current therapy options. Curr. Treat. Options Oncol. 7(5), 410-423 (2006).
50. Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmes P: Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother. Pharmacol. 35(1), 1-9 (1994).
51. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA: Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, PEGylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 43(1), 1-7 (1999).
52. Veal GJ, Griffn MJ, Price E et al.: A Phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br. J. Cancer 84(8), 1029-1035 (2001).
53. Kim ES, Lu C, Khuri FR et al.: A Phase II study of stealth cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 34(3), 427-432 (2001).
54. Harrington KJ, Lewanski CR, Northcote AD et al.: Phase I-II study of PEGylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann. Oncol. 12(4), 493-496 (2001).
55. Meerum Terwogt JM, Groenewegen G, Pluim D et al.: Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother. Pharmacol. 49(3), 201-210 (2002).
56. Rosenthal DI, Yom SS, Liu L et al.: A Phase I study of SPI-077 (stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest. New Drugs 20(3), 343-349 (2002).
57. Vokes EE, Gordon GS, Mauer AM et al.: A Phase I study of stealth cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung cancer. Clin. Lung Cancer 2(2), 128-132 (2000).
58. White SC, Lorigan P, Margison GP et al.: Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br. J. Cancer 95(7), 822-828 (2006).
59. Lee JH, Lee JM, Kim JK et al.: Antitumor activity of 7-[2-(N- isopropylamino) ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res. 21(5), 581-590 (1998).
60. ® liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models. Anticancer Res. 27(4B), 2541-2545 (2007).
61. Zamboni WC, Strychor S, Joseph E et al.: Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin. Cancer Res. 13(23), 7217-7223 (2007).
62. Zamboni WC, Strychor S, Maruca L et al.: Pharmacokinetic study of PEGylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin. Pharmacol. Ther. 86(5), 519-526 (2009).
63. Allen TM, Cullis PR: Drug delivery systems: entering the mainstream. Science 303(5665), 1818-1822 (2004).
64. Maeda H, Bharate GY, Daruwalla J: Polymeric drugs for effcient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71(3), 409-419 (2009).
65. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007).
66. Hobbs SK, Monsky WL, Yuan F et al.: Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95(8), 4607-4612 (1998).
67. Yuan F, Dellian M, Fukumura D et al.: Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55(17), 3752-3756 (1995).
68. Greish K: Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target 15(7-8), 457-464 (2007).
69. Massey KA, Schnitzer JE: Caveolae and cancer. Recent Results Cancer Res. 180, 217-231 (2010).
70. Heldin CH, Rubin K, Pietras K, Östman A: High interstitial fuid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 4(10), 806-813 (2004).
71. Vert M: Degradable and bioresorbable polymers in surgery and in pharmacology: beliefs and facts. J. Mater. Sci. Mater. Med. 20(2), 437-446 (2009).
72. Passirani C, Barratt G, Devissaguet JP, Labarre D: Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci. 62(8), 775-785 (1998). (Pubitemid 28062593)
73. Wang ZY, Stern IJ: Disposition in rats of a polyoxypropylene- polyoxyethylene copolymer used in plasma fractionation. Drug Metab. Dispos. 3(6), 536-542 (1975).
74. Kwon GS, Yokoyama M, Okano T, Sakurai Y, Kataoka K: Biodistribution of micelle-forming polymer-drug conjugates. Pharm. Res. 10(7), 970-974 (1993).
75. Hunter AC, Moghimi SM: Therapeutic synthetic polymers: a game of Russian roulette? Drug Discov. Today 7(19), 998-1001 (2002).
76. Li S-D, Huang L: Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta 1788(10), 2259-2266 (2009).
77. Sheng Y, Liu C, Yuan Y et al.: Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials 30(12), 2340-2348 (2009).
78. Shan X, Liu C, Yuan Y et al.: In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)- modifed PLA (BAB type) triblock copolymer. Colloids Surf. B. Biointerfaces 72(2), 303-311 (2009).
79. Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H: Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release 88(1), 35-42 (2003). (Pubitemid 36173950)
80. Ishida T, Kiwada H: Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354(1-2), 56-62 (2008).
81. Ishida T, Ichihara M, Wang X, Kiwada H: Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 115(3), 243-250 (2006).
82. Wang X, Ishida T, Kiwada H: Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release 119(2), 236-244 (2007).
83. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ: Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J. Pharmacol. Exp. Ther. 312(3), 1020-1026 (2005).
84. Laverman P, Carstens MG, Boerman OC et al.: Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther. 298(2), 607-612 (2001).
85. Ishihara T, Takeda M, Sakamoto H et al.: Accelerated blood clearance phenomenon upon repeated injection of PEG-modifed PLA-nanoparticles. Pharm. Res. 26(10), 2270-2279 (2009).
86. Lu W, Wan J, She Z, Jiang X: Brain delivery property and accelerated blood clearance of cationic albumin conjugated PEGylated nanoparticle. J. Control. Release 118(1), 38-53 (2007).
87. Koide H, Asai T, Hatanaka K et al.: Particle size-dependent triggering of accelerated blood clearance phenomenon. Int. J. Pharm. 362(1-2), 197-200 (2008).
88. Romberg B, Metselaar JM, deVringer T et al.: Enzymatic degradation of liposome-grafted poly(hydroxyethyl L-glutamine). Bioconjug. Chem. 16(4), 767-774 (2005).
89. Judge A, McClintock K, Phelps JR, Maclachlan I: Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 13(2), 328-337 (2006).
90. Xu H, Wang KQ, Deng YH, Chen da W: Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials 31(17), 4757-4763 (2010).
91. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR: Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target 10(4), 327-335 (2002).
92. Duncan R: Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6(9), 688-701 (2006).
93. Hong RL, Huang CJ, Tseng YL et al.: Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol benefcial? Clin. Cancer Res. 5(11), 3645-3652 (1999).
94. Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L: Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control. Release 91(3), 417-429 (2003).
95. Yang T, Cui FD, Choi MK et al.: Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int. J. Pharm. 338(1-2), 317-326 (2007).
96. Byrne JD, Betancourt T, Brannon-Peppas L: Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 60(15), 1615-1626 (2008).
97. Maruyama K: PEG-immunoliposome. Biosci. Rep. 22(2), 251-266 (2002).
98. Marcucci F, Lefoulon F: Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov. Today 9(5), 219-228 (2004).
99. Allen TM: Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2(10), 750-763 (2002).
100. Weiner LM, Adams GP: New approaches to antibody therapy. Oncogene 19(53), 6144-6151 (2000).
101. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J: Targeting cancer cells using PLGA nanoparticles surface modifed with monoclonal antibody. J. Control. Release 120(1-2), 18-26 (2007).
102. Elbayoumi TA, Torchilin VP: Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modifed doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur. J. Pharm. Sci. 32(3), 159-168 (2007).
103. Gupta B, Torchilin VP: Monoclonal antibody 2C5-modifed doxorubicin-loaded liposomes with signifcantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother. 56(8), 1215-1223 (2007).
104. Presta LG: Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev. 58(5-6), 640-656 (2006).
105. Kou G, Gao J, Wang H et al.: Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J. Biochem. Mol. Biol. 40(5), 731-739 (2007).
106. Kirpotin DB, Shao Y: Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732-6740 (2006).
107. Park J W, Hong K, Kirpotin DB et al.: Anti-HER2 immunoliposomes: enhanced effcacy attributable to targeted delivery. Clin. Cancer Res. 8(4), 1172-1181 (2002).
108. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM: Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239(2), 133-144 (1995).
109. Popielarski SR, Pun SH, Davis ME: A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 1. Synthesis and characterization. Bioconjug. Chem. 16(5), 1063-1070 (2005).
110. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E: Nanocrystal targeting in vivo. Proc. Natl Acad. Sci. USA 99(20), 12617-12621 (2002).
111. Gref R, Couvreur P, Barratt G, Mysiakine E: Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 24(24), 4529-4537 (2003).
112. Beduneau A, Saulnier P, Benoit JP: Active targeting of brain tumors using nanocarriers. Biomaterials 28(33), 4947-4967 (2007).
113. Matzku S, Krempel H, Weckenmann HP, Schirrmacher V, Sinn H, Stricker H: Tumor targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver metastases. Cancer Immunol. Immunother. 31(5), 285-291 (1990).
114. Arruebo M, Valladares M, González-Fernández A: Antibody-conjugated nanoparticles for biomedical applications. J. Nanomaterials 2009, 439389 (2009).
115. Nimjee SM, Rusconi CP, Sullenger BA: Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555-583 (2005).
116. Blank M, Blind M: Aptamers as tools for target validation. Curr. Opin. Chem. Biol. 9(4), 336-342 (2005).
117. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R: Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 64(21), 7668-7672 (2004).
118. Farokhzad OC, Cheng J, Teply BA et al.: Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103(16), 6315-6320 (2006).
119. Cheng J, Teply BA, Sherif I et al.: Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5), 869-876 (2007).
120. Temming K, Schiffelers RM, Molema G, Kok RJ: RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumor vasculature. Drug Resist. Updat. 8(6), 381-402 (2005).
121. Schiffelers RM, Koning GA, Ten Hagen TL et al.: Anti-tumor effcacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release 91(1-2), 115-122 (2003).
122. Sugahara KN, Teesalu T, Karmali PP et al.: Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16(6), 510-520 (2009).
123. Alexis F, Rhee J W, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC: New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 26(1), 74-85 (2008).
124. Wang S, Low PS: Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J. Control. Release 53(1-3), 39-48 (1998).
125. Barratt GM: Therapeutic applications of colloidal drug carriers. Pharm. Sci. Technol. Today 3(5), 163-171 (2000).
126. Morille M, Passirani C, Letrou-Bonneval E, Benoit JP, Pitard B: Galactosylated DNA lipid nanocapsules for effcient hepatocyte targeting. Int. J. Pharm. 379(2), 293-300 (2009).
127. Pirollo KF, Chang EH: Does a targeting ligand infuence nanoparticle tumor localization or uptake? Trends Biotechnol. 26(10), 552-558 (2008).
128. Faraji AH, Wipf P: Nanoparticles in cellular drug delivery. Bioorg. Med. Chem. 17(8), 2950-2962 (2009).
129. Ruoslahti E, Bhatia SN, Sailor MJ: Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188(6), 759-768 (2010).
130. Maruyama K, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M: Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 413(1), 177-180 (1997).
131. Eaton M: Nanomedicine: industry-wise research. Nat. Mater. 6(4), 251-253 (2007).
132. Torchilin V: Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. 71(3), 431-444 (2009).
133. Breunig M, Bauer S, Goepferich A: Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur. J. Pharm. Biopharm. 68(1), 112-128 (2008).
134. Van Butsele K, Jérôme R, Jérôme C: Functional amphiphilic and biodegradable copolymers for intravenous vectorisation. Polymer 48(26), 7431-7443 (2007).
135. Van Butsele K, Sibret P, Fustin CA et al.: Synthesis and pH-dependent micellization of diblock copolymer mixtures. J. Colloid Interface Sci. 329(2), 235-243 (2009).
136. Gullotti E, Yeo Y: Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol. Pharm. 6(4), 1041-1051 (2009).
137. Vittaz M, Bazile D, Spenlehauer G et al.: Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials 17(16), 1575-1581 (1996).
138. Dos Santos N, Allen C, Doppen AM et al.: Infuence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim. Biophys. Acta 1768(6), 1367-1377 (2007).
139. Yang T, Cui FD, Choi MK et al.: Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int. J. Pharm. 338(1-2), 317-326 (2007).
140. Unezaki S, Maruyama K, Hosoda JI et al.: Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fuorescence microscopy Int. J. Pharm. 144(1), 11-17 (1996).
141. Unezaki S, Maruyama K, Ishida O, Suginaka A, Hosoda JI, Iwatsuru M: Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol). Int. J. Pharm. 126(1-2), 41-48 (1995).
142. Hoarau D, Delmas P, David S, Roux E, Leroux JC: Novel long-circulating lipid nanocapsules. Pharm. Res. 21(10), 1783-1789 (2004).
143. Khalid MN, Simard P, Hoarau D, Dragomir A, Leroux JC: Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm. Res. 23(4), 752-758 (2006).
144. Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L: Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control. Release 63(1-2), 19-30 (2000).
145. Bocca C, Caputo O, Cavalli R, Gabriel L, Miglietta A, Gasco MR: Phagocytic uptake of fuorescent stealth and non-stealth solid lipid nanoparticles. Int. J. Pharm. 175(2), 185-193 (1998).
146. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR: Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res. 42(4), 337-343 (2000).
147. Podio V, Zara GP, Carazzone M, Cavalli R, Gasco MR: Biodistribution of stealth and non-stealth solid lipid nanospheres after intravenous administration to rats. J. Pharm. Pharmacol. 52(9), 1057-1063 (2000).
148. Beduneau A, Saulnier P, Anton N et al.: PEGylated nanocapsules produced by an organic solvent-free method: evaluation of their stealth properties. Pharm. Res. 23(9), 2190-2199 (2006).
149. Gref R, Luck M, Quellec P et al.: 'Stealth' corona-core nanoparticles surface modifed by polyethylene glycol (PEG): infuences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B. Biointerfaces 18(3-4), 301-313 (2000).
150. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M: Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84(4), 493-498 (1995).
151. Verrecchia T, Spenlehauer G, Bazile DV, Murry-Brelier A, Archimbaud Y, Veillard M: Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J. Control. Release 36(1-2), 49-61 (1995).
152. Shan X, Yuan Y, Liu C, Xu F, Sheng Y: Comparison of the PLA-mPEG and mPEG-PLA-mPEG copolymers nanoparticles on the plasma protein adsorption and in vivo biodistribution. Soft Matter 5(15), 2875-2883 (2009).
153. Dong Y, Feng SS: In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (mPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials 28(28), 4154-4160 (2007).
154. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K: Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J. Control. Release 77(1-2), 27-38 (2001).
155. Mattheolabakis G, Taoufk E, Haralambous S, Roberts ML, Avgoustakis K: In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur. J. Pharm. Biopharm. 71(2), 190-195 (2009).
156. Park J, Fong PM, Lu J et al.: PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine 5(4), 410-418 (2009).
157. Avgoustakis K, Beletsi A, Panagi Z et al.: Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int. J. Pharm. 259(1-2), 115-127 (2003).
158. Li Y, Pei Y, Zhang X et al.: PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control. Release 71(2), 203-211 (2001).
159. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K: Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int. J. Pharm. 221(1-2), 143-152 (2001).
160. Danhier F, Lecouturier N, Vroman B et al.: Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J. Control. Release 133(1), 11-17 (2009).
161. Senthilkumar M, Mishra P, Jain NK: Long circulating PEGylated poly(D,L-lactide-co-glycolide) nanoparticulate delivery of docetaxel to solid tumors. J. Drug Target 16(5), 424-435 (2008).
162. Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K: Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur. J. Pharm. Biopharm. 67(1), 1-8 (2007).
163. Peracchia MT, Fattal E, Desmaele D et al.: Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 60(1), 121-128 (1999).
164. Huang M, Wu W, Qian J, Wan DJ, Wei XL, Zhu JH: Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-N-hexadecyl cyanoacrylate nanoparticles. Acta Pharmacol. Sin. 26(12), 1512-1518 (2005).
165. Calvo P, Gouritin B, Chacun H et al.: Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18(8), 1157-1166 (2001). (Pubitemid 32900402)
166. Brigger I, Morizet J, Aubert G et al.: Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther. 303(3), 928-936 (2002).
167. Kim HR, Gil S, Andrieux K et al.: Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol. Life Sci. 64(3), 356-364 (2007). (Pubitemid 46440206)
168. Kim HR, Andrieux K, Gil S et al.: Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 8(3), 793-799 (2007).
169. Zhang L, Hu Y, Jiang X, Yang C, Lu W, Yang YH: Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co- lactide) nanoparticles and their biodistribution in mice. J. Control. Release 96(1), 135-148 (2004).
170. Zhang L, Yang M, Wang Q et al.: 10-hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J. Control. Release 119(2), 153-162 (2007).
171. Gou M, Zheng X, Men K et al.: Poly(e-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. J. Phys. Chem. B 113(39), 12928-12933 (2009).
172. Nakada Y, Tudomi R, Sakurai K, Takahashi Y: Evaluation of long-circulating nanoparticles using biodegradable ABA triblock copolymers containing of poly(L-lactic acid) A-blocks attached to central poly(oxyethylene) B-blocks in vivo. Int. J. Pharm. 175(1), 109-117 (1998).
173. Matsumoto J, Nakada Y, Sakurai K, Nakamura T, Takahashi Y: Preparation of nanoparticles consisted of poly(-lactide)-poly(ethylene glycol)-poly(-lactide) and their evaluation in vitro. Int. J. Pharm. 185(1), 93-101 (1999).
174. He G, Ma LL, Pan J, Venkatraman S: ABA and BAB type triblock copolymers of PEG and PLA: a comparative study of drug release properties and "stealth" particle characteristics. Int. J. Pharm. 334(1-2), 48-55 (2007).
175. Redhead HM, Davis SS, Illum L: Drug delivery in poly(lactide-co- glycolide) nanoparticles surface modifed with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J. Control. Release 70(3), 353-363 (2001).
176. Metselaar JM, Bruin P, de Boer LW et al.: A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug. Chem. 14(6), 1156-1164 (2003).
177. Woodle MC, Engbers CM, Zalipsky S: New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug. Chem. 5(6), 493-496 (1994).
178. Torchilin V P, Shtilman MI, Trubetskoy VS, Whiteman K, Milstein AM: Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim. Biophys. Acta 1195(1), 181-184 (1994).
179. Torchilin V P, Trubetskoy VS, Whiteman KR, Caliceti P, Ferruti P, Veronese FM: New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J. Pharm. Sci. 84(9), 1049-1053 (1995).
180. Jeong YI, Jin SG, Kim IY et al.: Doxorubicin-incorporated nanoparticles composed of poly(ethylene glycol)-grafted carboxymethyl chitosan and antitumor activity against glioma cells in vitro. Colloids Surf. B. Biointerfaces 79(1), 149-155 (2010).
181. Chung YI, Kim JC, Kim YH et al.: The effect of surface functionalization of PLGA nanoparticles by heparin-or chitosan-conjugated Pluronic on tumor targeting. J. Control. Release 143(3), 374-382 (2010).
182. Rouzes C, Gref R, Leonard M, De Sousa Delgado A, Dellacherie E: Surface modifcation of poly(lactic acid) nanospheres using hydrophobically modifed dextrans as stabilizers in an o/w emulsion/evaporation technique. J. Biomed. Mater. Res. 50(4), 557-565 (2000).
183. Chauvierre C, Labarre D, Couvreur P, Vauthier C: Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm. Res. 20(11), 1786-1793 (2003).
184. Yang T, Choi MK, Cui FD et al.: Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm. Res. 24(12), 2402-2411 (2007).
185. Hu Z, Luo F, Pan Y et al.: Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery. J. Biomed. Mater. Res. A 85(3), 797-807 (2008).
186. Xiong XB, Huang Y, Lu WL et al.: Intracellular delivery of doxorubicin with RGD-modifed sterically stabilized liposomes for an improved antitumor effcacy: in vitro and in vivo. J. Pharm. Sci. 94(8), 1782-1793 (2005). (Pubitemid 41360872)
187. Xiong XB, Huang Y, Lu WL et al.: Enhanced intracellular delivery and improved antitumor effcacy of doxorubicin by sterically stabilized liposomes modifed with a synthetic RGD mimetic. J. Control. Release 107(2), 262-275 (2005). (Pubitemid 41316289)
188. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S: In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 9(17), 6551-6559 (2003).
189. Yoo HS, Park TG: Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Release 96(2), 273-283 (2004).
190. Jae HP, Kwon S, Lee M et al.: Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials 27(1), 119-126 (2006).
191. Drummond DC, Noble CO, Guo Z et al.: Development of a highly stable and targetable nanoliposomal formulation of topotecan. J. Control. Release 141(1), 13-21 (2010).
192. Utreja P, Jain S, Tiwary AK: Novel drug delivery systems for sustained and targeted delivery of anti-cancer drugs: current status and future prospects. Curr. Drug Deliv. 7(2), 152-161 (2010).
193. Graul AI, Prous JR, Barrionuevo M et al.: The year's new drugs and biologics-2007. Drug News Perspect. 21(1), 7-35 (2008).
194. Hamaguchi T, Kato K, Yasui H et al.: A Phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br. J. Cancer 97(2), 170-176 (2007).
195. Bharali DJ, Mousa SA: Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol. Ther. 128(2), 324-35 (2010).
196. Krown SE, Northfelt DW, Osoba D, Stewart JS: Use of liposomal anthracyclines in Kaposi's sarcoma. Semin. Oncol. 31(6 Suppl. 13), 36-52 (2004).
197. Rose PG: PEGylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10(3), 205-214 (2005).
198. Matsumura Y, Hamaguchi T, Ura T et al.: Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 91(10), 1775-1781 (2004).
199. Hamaguchi T, Matsumura Y, Nakanishi Y et al.: Antitumor effect of MCC-465, PEGylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci. 95(7), 608-613 (2004).
200. Matsumura Y, Gotoh M, Muro K et al.: Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15(3), 517-525 (2004).
201. Schwendener RA, Horber DH, Rentsch K, Hanseler E, Pestalozzi B, Sauter C: Preclinical and clinical experience with liposome-encapsulated mitoxantrone. J. Liposome Res. 4(1), 605-639 (1994).
202. Seetharamu N, Kim E, Hochster H, Martin F, Muggia F: Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res. 30(2), 541-545 (2010).
203. Boulikas T: Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin. Investig. Drugs 18(8), 1197-1218 (2009).
204. Boulikas T: Low toxicity and anticancer activity of a novel liposomal cisplatin (lipoplatin) in mouse xenografts. Oncol. Rep. 12(1), 3-12 (2004).
205. Uchino H, Matsumura Y, Negishi T et al.: Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br. J. Cancer 93(6), 678-687 (2005).
206. Zamboni WC, Ramalingam S, Friedland DM et al.: Phase I and pharmacokinetic study of PEGylated liposomal CKD-602 in patients with advanced malignancies. Clin. Cancer Res. 15(4), 1466-1472 (2009).
207. Matsumura Y: Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv. Drug Deliv. Rev. DOI: 10.1016/j. addr.2010.05.008 (2010) (Epub ahead of print).
208. Matsumura Y, Kataoka K: Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100(4), 572-579 (2009).